Momelotinib (Ojjaara) is an innovative cancer drug designed to treat myelofibrosis, a serious condition characterized by bone marrow scarring and anemia. While this medication offers significant therapeutic benefits, it is crucial for patients to be aware of potential side effects and take necessary precautions. Understanding these aspects can help manage the treatment more effectively and minimize risks.

Momelotinib (Ojjaara) Side Effects

Momelotinib, while effective in treating myelofibrosis, can cause various side effects that require careful monitoring and management. Here are some of the most common and potentially serious side effects:

Infection Risk

Patients taking Momelotinib have a higher risk of developing infections, including severe or even fatal ones. Bacterial and viral infections, such as COVID-19, are particularly concerning. Approximately 38% of patients experience infections, with 13% having severe cases. It is essential to delay starting Momelotinib until any active infections are resolved. Regularly monitor for signs of infection and initiate appropriate treatment promptly.

Blood Cell Count Changes

Momelotinib can lead to blood cell count changes, specifically thrombocytopenia (low platelet count) and neutropenia (low neutrophil count). About 20% of patients develop new or worsened thrombocytopenia, with platelet counts dropping below 50×10⁹/L. For patients with baseline platelet counts already below 50×10⁹/L, the risk is even higher. Regular blood tests are necessary to monitor these levels and adjust the dosage if needed.

Liver Toxicity

Momelotinib has been associated with liver toxicity, which can manifest as acute or chronic liver disease. Before starting the treatment, investigate and address any underlying causes of liver issues. Patients should undergo regular liver function tests, especially during the first six months of treatment. If uncontrolled liver problems occur, delay the start of Momelotinib until the cause is identified and managed.

Understanding and managing these side effects is crucial for ensuring the safety and effectiveness of Momelotinib therapy.

Using Momelotinib (Ojjaara) Safely

To maximize the benefits of Momelotinib while minimizing risks, patients should adhere to specific guidelines and precautions. These recommendations cover various aspects of the treatment process, from initial assessment to ongoing monitoring.

Initial Assessment and Monitoring

Before starting Momelotinib, patients should undergo a thorough medical evaluation. This includes:

• Complete blood count (CBC)
• Liver function tests
• Assessment of cardiovascular health

Regular follow-up visits are essential to monitor for any adverse effects and adjust the treatment plan as needed. Patients should report any new or worsening symptoms to their healthcare provider immediately.

Dosage Adjustments

The recommended dose of Momelotinib is 200mg, taken orally once daily. However, dosage adjustments may be necessary based on individual patient factors:

• Severe Liver Impairment: For patients with Child-Pugh Class C liver impairment, the initial dose should be reduced to 150mg daily.
• Uncontrollable Side Effects: If patients cannot tolerate the standard dose, the dosage can be reduced to 100mg daily. If side effects persist, consider discontinuing the medication.

Patients should never cut, crush, or chew the tablets; they should be swallowed whole with or without food.

Special Populations

Certain groups of patients require special consideration when using Momelotinib:

• Pregnant Women: Limited data exists on the use of Momelotinib during pregnancy. The drug may pose risks to the fetus, so it should only be used if the benefits outweigh the potential risks.
• Breastfeeding Women: There is no information on whether Momelotinib passes into breast milk. Patients should avoid breastfeeding during treatment and for at least one week after the last dose.

Healthcare providers should carefully evaluate the risks and benefits for each patient, especially those with pre-existing conditions or who are part of vulnerable populations.

By following these guidelines and maintaining open communication with healthcare providers, patients can safely and effectively use Momelotinib to manage their myelofibrosis and improve their quality of life.